POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Chest. 2016 Aug;150(2):273-5. doi: 10.1016/j.chest.2016.04.034. Epub 2016 Jun 9.

Authors

Christopher S King¹, Steven D Nathan²

Affiliations

¹ Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA. Electronic address: christopher.king@inova.org.
² Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA.

PMID: 27292047
DOI: 10.1016/j.chest.2016.04.034

No abstract available

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antineoplastic Agents / therapeutic use
Decision Making*
Humans
Idiopathic Pulmonary Fibrosis / diagnosis
Idiopathic Pulmonary Fibrosis / drug therapy*
Indoles / therapeutic use*
Pyridones / therapeutic use*
Severity of Illness Index
Tumor Necrosis Factor-alpha

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Indoles
Pyridones
Tumor Necrosis Factor-alpha
pirfenidone
nintedanib